NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Vittoria Biotherapeutics

Vittoria Biotherapeutics

Private
Philadelphia, PennsylvaniaHealthcare & Life Scienceshttps://vittoriabio.com/

Last Round

Private Financing

Extension

Nov 12, 2024

Total Funding Raised

$35M

Company Overview

Vittoria Biotherapeutics is a biotechnology company developing novel CAR T-cell therapies that transcend the limitations of current cell therapies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

CAR-T cell therapycell therapygene editingimmunotherapyautologous cell therapynext-gen CAR-TT-cell lymphomahematological malignanciesbiotechclinical-stage biotechcell manufacturingprecision medicineoncologyautoimmune diseaseliving drugs

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Vittoria Biotherapeutics Comps

Public and private peers based on sector, stage, and business model.

Vittoria Biotherapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Vittoria Biotherapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Private Financing ExtensionNov 12, 2024
Series ANov 14, 2023
SeedJun 7, 2022

Key People

Founding team and executive leadership

Nicholas Siciliano

Chief Executive Officer

Executive Team

Keith Westby

Chief Operating Officer

Executive Team

Vittoria Biotherapeutics Investors

Notable investors and investment history

Vittoria Biotherapeutics investors
InvestorRounds
Agent CapitalPrivate Financing Extension, Seed, Series A
University of PennsylvaniaPrivate Financing Extension, Series A
RM Global PartnersPrivate Financing Extension
Tellus BioVenturesPrivate Financing Extension, Seed, Series A
Valley Forge Investment CorporationPrivate Financing Extension, Series A
The Leukemia & Lymphoma Society (LLS) Therapy Acceleration Program (TAP)Series A
BioAdvance CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 3, 2025

    Attended the 10th annual Penn Center for Innovation's Celebration of Innovation.

  • Dec 3, 2025

    Recognized for advancements in cellular therapy for T-cell lymphoma.

Vittoria Biotherapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Vittoria Biotherapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Vittoria Biotherapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersPhiladelphia, Pennsylvania
Employee Range14
Year Founded2021
Last FundingNov 12, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.